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Dopamine D2 receptors contribute to the inverted U-shaped relationship between dopamine 
signalling and prefrontal function. Genetic networks from post-mortem human brain revealed 
84 partner genes co-expressed with DRD2. Moreover, eight functional single nucleotide 
polymorphisms combined into a polygenic co-expression index (PCI) predicted co-
expression of this DRD2 network and were associated with PFC function in humans. Here, 
we investigated the non-linear association of the PCI with behavioural and WM-related brain 
response to pharmacological D2Rs stimulation.  
Fifty healthy volunteers took part in a double-blind, placebo-controlled, fMRI study with 
bromocriptine and performed the N-Back task. The PCI×drug interaction was significant on 
both WM behavioural scores (p=.046) and related PFC activity (all corrected p<.05) using a 
polynomial PCI model. Non-linear responses under placebo were reversed by bromocriptine 
administration. fMRI results on placebo were replicated in an independent sample of 50 
participants who did not receive drug administration (p=.034). 
These results match earlier evidence in non-human primates and confirm the physiological 
relevance of this DRD2 co-expression network. Results show that in healthy subjects 
different alleles evaluated as an ensemble are associated with non-linear PFC responses. 
Therefore, brain response to a dopaminergic drug may depend on a complex system of allelic 







Converging evidence from animal and human studies indicates that dopamine (DA) plays a 
key role in Working Memory (WM) (Williams and Goldman-Rakic 1995; Murphy et al. 
1996; Mattay et al. 2000; Mehta et al. 2000; Chudasama and Robbins 2004; Zhang et al. 
2007; Sambataro et al. 2009; Cassidy et al. 2016). DA is thought to exert its effects on WM 
by regulating neuronal firing rates in recurrent circuits of the prefrontal cortex (PFC) 
(Goldman-Rakic 1995; Seamans and Yang 2004). Animal models show that the dose-
dependent relationship between DA signalling and neuronal firing rates in the PFC follows an 
inverted-U shaped response (Vijayraghavan et al., 2007). In the PFC, DA binds D1 and D2 
receptors (D2Rs) of pyramidal neurons and GABA interneurons (Durstewitz et al. 2000; 
Seamans and Yang 2004; Avery and Krichmar 2015). In particular, based on evidence from 
animal and human studies (Seamans and Yang 2004; Kahnt et al. 2015), D2Rs are thought to 
promote the maintenance of multiple and concurrent representations, although excessive 
D2R-mediated signalling has been proposed to decrease signal to noise ratio in the PFC. In 
line with this proposal, behavioural studies in humans have shown that D2R agonists like 
bromocriptine and pergolide and antagonists like sulpiride and haloperidol modulate 
behavioural WM performance (Luciana et al. 1992; Luciana and Collins 1997; Mehta et al. 
1999; 2001; Kimberg and D'Esposito 2003). 
Also inter-individual differences in WM performance are thought to depend on DA signalling 
in the PFC (Kimberg et al. 1997; Slifstein et al. 2015). Across subjects, intermediate levels of 
DA signalling are associated with optimal WM performance, while excessively low and high 
DA signalling are associated with suboptimal performance (Williams and Castner 2006; 
Cools and D'Esposito 2011). Inter-individual variation in WM performance is related with 
individual WM capacity, i.e., the limited amount of memory representations that can be 
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maintained and updated (Wilhelm et al. 2013). WM capacity and WM-related prefrontal 
activity have a heritability estimated up to 40 percent (Blokland et al. 2011; Fletcher et al. 
2014; Hansell et al. 2015); particularly for the N-back task see (Blokland et al. 2008; Vogler 
et al. 2014) and are associated with genetic variation in DA-related genes (reviewed by 
(Karlsgodt et al. 2011). For instance, it has been previously shown that functional genetic 
variants such as DRD2 rs1076560 and COMT Val158Met, which may modulate DA 
signalling, are also associated with WM performance and related brain activity (Zhang et al. 
2007; Bertolino et al. 2008; Sambataro et al. 2009; Cohen et al. 2016; Luykx et al. 2017). 
Previous evidence also shows a DA-related genetic component of WM variation in response 
to stimulation with dopaminergic drugs (Mattay et al. 2003; Gelao et al. 2014). 
However, previous studies have revealed that the genetic component of WM is complex 
(Blokland et al. 2016). Most functional genetic variants in the genome are in non-coding 
regions and are associated with epigenetic mechanisms of gene regulation. The regulation of 
gene expression is operated by transcription factors and non-coding RNAs affecting multiple 
genes, and thus multiple genes converge into co-expression pathways (Gaiteri et al. 2014). 
These pathways are reflected in co-expression patterns (Eisen et al. 1998). In this regard, we 
recently employed co-expression networks to analyse the complex genetic component of DA-
related system-level phenotypes (Pergola et al. 2017). We examined the co-expression 
partners of DRD2 and identified a cluster of 84 genes co-expressed with DRD2. Then, we 
identified functional single nucleotide polymorphisms (SNPs) predicting expression of the 
whole DRD2 network and we combined them into a polygenic co-expression index (PCI) – 
thus indexing DRD2 gene set co-expression. Critically, the PCI/co-expression relationship 
was replicated in an independent post-mortem dataset. We also provided biological validation 
of the PCI by investigating its association with PFC function during WM in healthy 
individuals and with clinical response to D2R blockade in patients with schizophrenia. Both 
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findings were replicated in independent samples. Notably, previous studies investigated the 
effects on brain response to pharmacological stimulation of single functional SNPs within 
candidate genes (Jacobsen et al. 2006; Kirsch et al. 2006; London et al. 2009; Park et al. 
2012; Gelao et al. 2014; Kasparbauer et al. 2014). However, the cumulative effect of multiple 
alleles has been reported to increase the effect size in association studies, including imaging 
genetics studies (Mattingsdal et al. 2013; Walton et al. 2013; Dima and Breen 2015; Pergola 
et al. 2016), even though the molecular mechanisms of SNPs are still unknown. While the 
evidence from our previous study supports the combination of multiple SNPs to investigate 
the neurobiology of WM, it is unclear whether the ensemble of these functional SNPs can be 
used to predict how the same individual responds to pharmacological challenges in a double-
blind trial.  
Here, we explored whether the PCI interacts with the effect of D2R targeting drugs on WM 
capacity and related brain activity. Since WM capacity in humans is limited, inter-individual 
differences emerge most clearly when considering individual performance at multiple, 
challenging WM loads (Callicott, Mattay, Bertolino, Finn, Coppola, Frank, Goldberg, and 
Weinberger 1999a; Van Snellenberg et al. 2015). Thus, we investigated whether individual 
performance at multiple loads reflecting inter-individual heterogeneity in WM capacity is 
related with genetic variation in genes involved in DRD2 co-expression.  
In particular, we tested in healthy humans, thus independently of any disease-specific 
pathophysiological confound, whether allelic patterns of co-expression partner genes of 
DRD2 are associated with behavioral and brain responses to D2R stimulation during WM 
following an inverted U-shaped model (Cools and D'Esposito 2011). We hypothesized that 
individual response to D2R targeting drugs in terms of WM capacity and modulation of PFC 
activity depends upon a complex individual genetic background co-expressed with DRD2. 
We performed a cross-over, double-blind, placebo controlled, randomized, genetic study with 
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bromocriptine (BRO) administration, a D2R agonist with high affinity (Sautel et al. 1995). 
We indexed inter-individual variability in WM as the difference between the 3-back and 2-
back in behavioural accuracy (percent of correct response) as well as its underlying prefrontal 
activity (ΔWM). This approach is intended to obtain a metric with greater variability across 
individuals, because n-back accuracy is prone to ceiling effects (Callicott, Mattay, Bertolino, 
Finn, Coppola, Frank, Goldberg, and Weinberger 1999b; Van Snellenberg et al. 2015), which 
may bias the association with a continuous genetic index. Since differential accuracy is 
associated with the increase of cognitive load, less negative values are interpreted as 
representing greater WM capacity, i.e., more consistent accuracy in the face of load increase.   
It is not possible to estimate DA concentration in the PFC based on genetic markers, but 
given the inverted U-shaped relationship between WM and DA signalling, we hypothesized 
that the effect of BRO on ΔWM would depend on a quadratic term of the PCI reflecting DRD2 
co-expression. Currently available data support the inverted U-shaped model with DA 
concentration and D1 stimulation (Seamans and Young, 2004), as well as with genetically 
predicted availability of NMDA subunits (Pergola et al., 2016), but this is the first study to 
test this model with regard to D2Rs. Since DA acts on multiple neural pathways, we provided 
further systems-level validation of the findings outside the PFC. To this aim, we tested the 
association of the PCI with blood prolactin levels, which are modulated by D2Rs and affected 
by BRO administration (Berry and Gudelsky 1991). Finally, we replicated the results 
obtained in the placebo condition in an independent dataset we reported previously (Pergola 
et al. 2017). 
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Seventy-one healthy volunteers (34 males, age mean+SD 26.4+5.1 years; 36 overlapping 
with the sample tested by (Gelao et al. 2014) were enrolled in the bromocriptine study. 
Before entering the study, all participants underwent a screening visit in which inclusion and 
exclusion criteria were evaluated. A medical assessment was performed by a trained 
physician, including medical history, physical exam and blood testing. Inclusion criteria were 
the absence of any psychiatric disorder, as evaluated with the Structured Clinical Interview 
for DSM-IV (First et al. 1997), Intelligence Quotient (IQ) > 80, as evaluated with the 
Wechsler Adult Intelligence Scale-Revised (Wechsler 1981), and age between 18 and 65 
years. Since differential accuracy is not recommended as a WM performance index for 
participants with low accuracy (Cassidy et al., 2016), we only included individuals with 
above-chance accuracy at all loads considered (see Supplementary Materials, Section 3). 
Exclusion criteria were any neurological or medical condition considered as clinically 
significant or possibly interfering with the study by the physician during the screening visit, 
history of head trauma with loss of consciousness or drug abuse, hyperprolactinemia and any 
continuous pharmacological treatment in the past month. Substance abuse and substance 
dependence conditions (including alcohol) was excluded via a semi-structured interview 
based on DSM-IV-TR (SCID). Additional exclusion criteria were pregnancy or breastfeeding 
and use of oral contraceptives for female participants. On the same occasion, demographic 
and neuropsychological data were collected. In particular, the Hollingshead Scale 
(Hollingshead and Redlich 1958) was used to measure the socioeconomic status and the 
Edinburgh Inventory (Oldfield 1971) to evaluate handedness. 
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All subjects were unrelated Caucasians from the region of Apulia, Italy. After detailed 
description of the protocol, participants provided written informed consent according to the 
Declaration of Helsinki. The protocol was approved by the local ethics committee.  
The entire sample was used for the analysis on prolactin peripheral levels. fMRI and 
behavioural analyses were performed on a subsample of 50 participants (27 males, mean age 
± SD, 27.0 ± 4.1 years), who had no missing structural and functional MRI data and whose 
scans were considered adequate after a technical quality check (Supplemental Material and 
Methods, Section 3). Excluded participants did not differ with the analysis sample in terms of 
sociodemographic characteristic, IQ and PCI (all p >.1). Table 1 shows the sociodemographic 
characteristics of the sample.    
In order to replicate part of the results obtained in the present study, we re-analysed 
data from our previous study (see Pergola et al. 2017 for details). In particular, we selected all 
participants from the fMRI study who performed the 3-back task (50 participants; see table 
1). 
 
Table 1 about here 
 
Experimental procedure in the bromocriptine study 
Participants underwent a double blind, randomized, placebo controlled, crossover trial with 
oral administration of BRO 1.25 mg as previously described (Gelao et al. 2014). Briefly, 
participants were scanned twice (two weeks apart), once after administration of BRO and 
once after lactose placebo (PLA). The order of administration, i.e., PLA first or BRO first, 
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was counterbalanced across participants. BRO and PLA were administered orally in identical 
capsules 150 minutes before the fMRI scan according to previous estimations of the time to 
reach peak of plasma concentrations (90-180 minutes) and of elimination half-life (Kvernmo 
et al. 2006). Domperidone (a peripheral selective D2 antagonist which does not cross the 
blood-brain barrier, (Shindler et al. 1984) 10 mg was administered orally 30 minutes before 
both BRO and PLA to prevent possible side effects induced by BRO intake. The dosage of 
1.25 mg was chosen as previous studies consistently reported that it was able to modulate 
behaviour and BOLD signal during WM and was not associated with significant adverse 
events (Luciana et al. 1992; Mehta et al. 2001). Nobody spontaneously reported any adverse 
event on study days.  
 
Weighted Genes Co-Expression Network Analysis and Polygenic Co-Expression Index. 
A polygenic co-expression index (PCI) was calculated as described in detail elsewhere 
(Pergola et al. 2017). Briefly, the Braincloud post mortem dataset 
(http://braincloud.jdmi.edu/; (Colantuoni et al. 2011) was used to perform a Weighted Genes 
Co-expression Network Analysis (Bin Zhang and Horvath 2005) in order to identify a DRD2 
co-expression gene set. This gene set included 85 genes (Table S1). A set of eight SNPs 
(Table 2) was significantly enriched for gene regulation function in the dorsolateral prefrontal 
cortex (DLPFC). The SNPs were associated with the co-expression of the entire gene set. The 
PCI was computed by assigning a weight to each genotype of each SNP based on the co-
expression profile of the gene set, such that greater PCI corresponded to greater predicted 
gene set co-expression for that individual (Pergola et al. 2016; 2017). Ethnicity, population 
stratification and age effects on the interaction between the PCI and post mortem gene 
expression were assessed elsewhere (Pergola et al. 2017). Our previous work has shown that 
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population stratification effects are negligible in this sample, likely because the catchment 
area was limited and only native Caucasians born in Apulia were included in the study. 
Furthermore, the association of the PCI with DRD2 co-expression was replicated in an 
independent post mortem dataset (BrainEAC, (Trabzuni et al. 2011). All participants were 
genotyped for the SNPs identified by (Pergola et al. 2017) to compute the PCI for each 
individual (for further details please see Supplemental Material and Methods and (Pergola et 
al. 2017). 
 
Table 2 about here 
 
Working Memory task 
During fMRI, participants performed two runs of a block design WM task: the N-back task 
(Blasi et al. 2015). Stimuli consisted of numbers (1-4) shown in a random sequence and 
displayed at the points of a diamond-shaped box. In the WM condition participants were 
required, at each trial, to press the button corresponding to the stimulus seen two (2-Back), or 
three stimuli (3-Back) previously presented, while keeping on encoding incoming stimuli. 
The non-memory control condition required to identify the stimuli currently presented (0-
Back). Both 2-Back and 3-Back were carried out by participants in two separate runs. In 
particular, each run consisted of 8 blocks of 30 seconds each. For the 2-Back run, four blocks 
of 0-Back (our control condition) were interleaved with the same number of 2-Back blocks 
(our experimental condition). This structure was identical for the 3-Back run. The same 
procedure has been followed for the participants in the replication sample (Pergola et al. 
2017). For each session, before entering the scanner, all participants performed a practice 
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session of both task runs to achieve stable performance. 
 
Behavioural data analysis 
We computed differential accuracy (from now also called behavioural ΔWM index) as the 
difference between 3- and 2-Back accuracy for both the bromocriptine and the replication 
samples and assessed whether it differed from zero using separate one-sample t-tests for the 
BRO and PLA conditions. We computed a repeated measures ANCOVA within SPSS (IBM 
SPSS Statistics, Version 22.0) to test the interaction between the PCI and BRO 
administration on behavioural data. Behavioural ΔWM index was the dependent variable, drug 
(BRO or PLA) was the repeated measures factor, gender was a between-subjects factor, 
linear, quadratic, and cubic terms (to ensure that the quadratic fit was indeed the best fit) of 
the PCI were the continuous predictors. We used the quadratic term of the PCI to test for the 
inverted U-shaped associations of behavioural ΔWM index with predicted transcription levels 
of the DRD2 co-expression network, as indexed by the PCI. Since we used a polynomial 
model, we also introduced first- (linear) and zero-degree (constant) terms to marginalize the 
quadratic term for lower degree effects. To test the robustness of our analysis reducing the 
effect of extreme observations we used the bias corrected accelerated bootstrap technique 
with 10,000 resamples, bias-corrected accelerated algorithm (Efron and Tibshirani 1986). A 
comparison of fits analysis (quadratic vs linear and cubic vs quadratic) was performed on the 
differences between BRO and PLA in behavioural ΔWM index marginalized by gender 
(Supplementary Materials, Section 4). Additionally, the Supplementary Material (Section 2) 
reports the results of further analyses addressing percent accuracy and reaction times 
separately by load. 
In the replication sample, we computed a general linear model with the behavioural ΔWM 
12 
 
index as the dependent variable, gender as a between-subjects factor, and the three 
polynomial terms of the PCI as continuous predictors. Following the results of the 
bromocriptine study, we estimated the t-parameter of the negative relationship between the 
quadratic PCI and behavioural the ΔWM index and computed one-tailed p-values, as we had a 
priori evidence on the negative relationship. 
 
fMRI data acquisition and analysis 
fMRI data were acquired for both the bromocriptine and the replication sample with a 3T 
MRI scanner (SIGNA, GE Healthcare) with a gradient-echo planar imaging (EPI) sequence 
and the following parameters: repetition time= 2,000 ms; echo time= 28 ms; 20 interleaved 
axial slices; thickness= 4 mm; gap= 1 mm; voxel size, 3.75 × 3.75 × 5 mm; flip angle= 90°; 
field of view= 24 cm; matrix= 64×64. The imaging stack of 100 mm did not fully cover the 
cerebellum and some inferior temporal regions. 120 volumes were acquired for each run of 
the N-Back task. The first four scans were discarded to allow for magnetic equilibration. In 
addition, structural scans were acquired using a T1-weighted SPGR sequence for co-
registration with fMRI (TE= min full; flip angle, 6°; field of view, 250 mm; bandwidth, 
31.25; matrix, 256 x 256; 124 1.3-mm-axial slices). Pre-processing and data analysis were 
performed using Statistical Parametric Mapping 8 (SPM8 v6313, 
http://www.fil.ion.ucl.ac.uk/spm) on MATLAB R2012b (The MathWorks, Inc., Natick, 
Massachusetts, United States) in a Linux environment. After quality check and de-noising 
obtained using the ArtRepair Software (Mazaika et al. 2009), images were reoriented 
(without reslice), corrected for slice acquisition time, realigned and unwarped (Andersson et 
al. 2001; Wilke 2012) using the first image as reference and then co-registered to the 
individuals’ structural T1 images. Scans were then resampled to 3.75 mm isotropic voxels and 
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normalized into a standard space (Montreal Neurological Institute, MNI) using a DARTEL 
template obtained from structural data. Thus, the images were smoothed with a Gaussian 
kernel of FWHM 10 mm (see Supplemental Material and Methods for a more detailed 
description of pre-processing). In the first-level analysis, linear contrasts were computed 
producing a contrast map at each voxel for the 2- > 0- and 3- > 0-Back conditions. Pre-
processing and first level GLM modelling were performed separately for the two runs. Both 
2-Back and 3-Back blocks were contrasted with 0-Back blocks within runs. Data were scaled 
at first-level within runs to adjust the signal for potential differences in intensity or in 
sensitivity to BOLD fluctuations between runs. To partially correct for slice-to-slice 
movement-induced signal loss, we computed framewise displacement (FD) (Power et al. 
2012) and censored the volumes with FD > 0.5 mm in the first level GLM model including a 
dummy regressor indicating each volume with significant estimated motion. In the 
bromocriptine study, to investigate the interaction between the PCI, BRO administration and 
WM load, we computed for each participant and each condition a map of the voxel-wise 
difference between 3-Back and 2-Back first-level maps using the imcalc function provided 
with SPM8 (http://tools.robjellis.net). Therefore, the difference in BOLD signal between the 
3- and 2-Back was our proxy for the neural correlates of inter-individual differences in brain 
activity during WM. These images entered a second-level analysis using a Flexible Factorial 
design in SPM8. Drug (BRO, PLA) was the repeated measure variable, linear, quadratic, and 
cubic terms of the PCI entered the model as continuous predictors. Gender was a nuisance 
factor. In the model design the main effect of subjects, the main effect of drug, the interaction 
between drug and each PCI term (linear, quadratic, and cubic) were computed. Cluster level 
family-wise error correction for multiple comparisons was performed as implemented in 
AFNI (-acf function; see (Cox et al. 2017) whole-brain corrected cluster defining threshold 
k=36, cluster-forming voxel p=.001, FWE-corrected p=.05). Finally, BOLD signal changes 
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were extracted from significant clusters and pooled using MarsBaR 
(http://marsbar.sourceforge.net/) for plotting the data. To test the robustness of our analysis 
reducing the effect of extreme observations we used the bias corrected accelerated bootstrap 
technique with 10,000 resamples (Efron and Tibshirani 1986). Comparison of fits analysis 
were performed also on the same BOLD data (Supplementary Materials and Methods, 
Section 4). 
To assess whether drug effects on behaviour and brain activity were related, we computed the 
difference between BRO and PLA on both behavioural and BOLD signal indices. Then, we 
assessed a linear model in SPSS in which the dependent variable was the behavioural effect 
of drug and the independent variable was the BOLD signal; consistent with all other analyses, 
we included gender in the model as a nuisance factor. 
In the replication sample, whose data were pre-processed as in our published report (see 
(Pergola et al. 2017) for details), we extracted the BOLD signal from the three significant 
clusters obtained in the bromocriptine study (see results below; these clusters are called 
regions of interest [ROI] in the following) and computed a repeated measures ANOVA with 
ROI as within-subjects factor, linear, quadratic, and cubic terms of the PCI as continuous 
predictors, and gender as a between-subjects factor. Following the results of the 
bromocriptine study, we estimated the t-parameter of the positive relationship between the 
quadratic PCI and BOLD variation and computed one-tailed p-values. 
 
Prolactin peripheral levels 
Two blood samples (immediately before, and at the end of the fMRI session, respectively) 
were obtained to measure peripheral prolactin levels. The two prolactin measures served to 
15 
 
test the known effect of BRO on prolactin levels: there is a physiological reduction of 
prolactin related with circadian rhythms and with the stress induced by the MRI scan (Dunn 
et al. 1972). Blood prolactin levels are modulated by DA in the tubero-infundibular pathway 
(Berry and Gudelsky 1991). Thus, we hypothesized an interaction between the PCI and 
prolactin level changes induced by BRO. For this analysis we considered the entire sample of 
71 participants and included gender in the model because of the well-known variation of 
prolactin peripheral levels in women (McNeilly and Chard 1974). Thus, we computed a 
repeated measures ANCOVA on prolactin levels, including the within-subject factors drug 
(BRO, PLA) and measurement (before or after fMRI), as well as the between-subject factor 






Differential accuracy was negative and significantly different from zero both on PLA (t49= -
4.2, p<.001) and on BRO (t49= -4.1, p<.001), indicating lower performance at 3- compared to 
2-back. Repeated measures ANCOVA on behavioural ΔWM index indicated a significant 
interaction between drug and the quadratic term of the PCI (F(1,45)= 4.2, p=.046, partial 
η2=.085, bootstrapped p=.074). The main effect of drug and the drug×linear PCI interaction 
were not significant (p > 0.05). Further behavioural analyses (Supplementary Materials, 
Section 2) did not identify significant drug×quadratic PCI effects irrespective of load, 
suggesting that the non-linear effect detected was specific to differential accuracy. Figure 1 
shows the scatterplot of the interaction. On PLA, very high or very low PCI scores were 
associated with a larger negative difference between accuracy at 3-Back and 2-Back. This 
finding implies that people with extreme PCI scores (i.e. with extreme allelic configurations) 
performed poorer at the highest WM load compared with people with an intermediate PCI 
score. This pattern of results was reversed on BRO, indicating that individuals with both high 
and low predicted DRD2 co-expression showed a larger response to BRO compared with 
individuals with intermediate PCI scores. Comparison of fits analysis revealed that the 
quadratic model was preferred to the linear model for this data (Supplementary Material, 
Section 2). Additionally, the analysis of reaction times revealed a positive relationship 
between reaction times and linear term of the PCI replicating our previous work (Pergola et 
al. (2017); see Supplementary Material, Section 2). 
The analysis on the replication sample, aimed to replicate the effect identified at placebo in 





Figure 1 about here 
 
Imaging data 
Table 3 reports the statistics and the localization of clusters of the main imaging results (3-
Back > 2-Back activity). We found a significant drug × quadratic PCI interaction in the right 
PFC, particularly in the superior, medial, middle, and inferior frontal gyri (bootstrap p=.006). 
No clusters were found outside the PFC. There were no other significant findings involving 
drug, PCI and drug × linear PCI interaction.  
 
Table 3 about here 
 
Figure 2B shows the scatterplot of the activity estimates extracted from the pooled clusters 
against the PCI. On PLA, the relationship between the PCI and prefrontal response was U-
shaped suggesting that subjects with extreme PCI scores (i.e. with extreme allelic 
configurations predicting high or low DRD2 co-expression levels), had a greater positive 
difference on activation between the two WM loads. In other words, they showed greater 
prefrontal activity at 3-Back compared to the 2-Back task. BRO administration inverted the 
U-shaped relationship: participants with extreme PCI scores had a greater negative difference 
on activation between the two conditions. This finding implies that, after BRO 
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administration, they had lower prefrontal activity while performing the 3-Back compared to 
the 2-Back task. Thus, also in this case individuals with high and low predicted DRD2 co-
expression levels showed a similar, large response to BRO. Like in behavioural data, 
comparison of fits revealed that the quadratic polynomial model was preferred to the linear 
and to the cubic model also for imaging data (see Supplementary Material and Methods). 
Further analyses on 2-Back vs 0-Back contrast and 3-Back vs 0-Back contrast separately 
(Supplementary Materials, Section 3) did not show significant clusters for the drug×quadratic 
PCI interaction, suggesting that the non-linear interaction detected was load-dependent. 
The drug effect on prefrontal activity was negatively correlated with the drug effect on 
behaviour (t47= -2.2, p=.03, partial eta squared=.096), suggesting that the findings in the 
BOLD response were related with WM performance of participants. The Supplementary 
Material (Section 3) reports the statistics in the BRO and PLA conditions separately, which 
revealed that the brain-behaviour correlation was significant at BRO and did not reach 
statistical significance at PLA.  
The analysis on the replication sample, aimed to replicate the effect identified at placebo in 
the bromocriptine study (Figure 2C), revealed no significant difference between the three 
ROIs and no significant PCI×ROI interaction. The ROIs derived from the discovery dataset 
overlapped with the WM network also in this dataset. The positive effect of the quadratic 
term of the PCI was significant also in the replication sample (t47= 1.9, one-tailed p=.034, 
partial η2=.073, bootstrap p=.018). 
 





Repeated measures ANCOVA on prolactin peripheral levels yielded significant main effects 
of drug (F(1,68) = 28; p < .001; partial η2=.29; BRO < PLA), measurement (F(1,68) = 110; p < 
.001; partial η2=.62; first > second), gender (F(1,68) = 85; p < .001; partial η2=.56; female > 
male), and PCI (F(1,68) = 4.4; p = .041; partial η2=.06; positively correlated with prolactin 
levels). We also found significant drug×PCI (F(1,68) = 4.4; p = .04; partial η2=.061), 
drug×gender (F(1,68) = 11; p = .002; partial η2=.14), and measurement×gender (F(1,68) = 31; p < 
.001; partial η2=.32) interactions. No other main effects or interactions were significant. We 
resolved the interaction involving the PCI by means of two post-hoc partial correlations 
controlled for gender (Bonferroni-corrected α = .025) and found that the PCI was associated 
with prolactin levels specifically on PLA (r = .28, p = .021), but not on BRO (r = .094, p = 
.44). The positive correlation indicates that higher predicted DRD2 expression levels were 





The present study aimed to investigate in healthy humans whether allelic patterns predicting 
the co-expression of a DRD2 gene set are associated with PFC function during WM to D2R 
stimulation. We found that the PCI predicting DRD2 co-expression interacted with BRO 
administration on i) WM differential accuracy ii) DLPFC activity during WM, and iii) 
prolactin peripheral levels. Furthermore, consistently with our hypothesis, the effect of BRO 
on ΔWM depended non-linearly on the PCI. These findings suggest that drug response to BRO 
co-varies with variation in multiple genes co-expressed with DRD2 (Pergola et al. 2017). 
Notably, different alleles in the same SNPs reflecting high or low DRD2 transcription levels 
were associated with similar behavioural and brain outcome, i.e., increased ΔWM and 
decreased DLPFC activity.  
 
Prefrontal function during working memory 
Both imaging and behavioural findings are consistent with previous studies reporting a 
modulatory effect of BRO on prefrontal function during WM (Kimberg et al. 2001; Gelao et 
al. 2014). Moreover, BRO administration interacts non-linearly with the PCI in both 
behavioural and fMRI analyses. Importantly, the behavioural pattern observed was opposite 
to the BOLD pattern, i.e., BOLD increase in the DLPFC was paralleled by poorer 
performance. This finding was further supported by the inverse correlation between 
behaviour and brain response. The inverse correlation can be interpreted in the context of 
WM efficiency (i.e. the amount of neural resources recruited for a certain level of 
performance; (Manoach 2003; Bertolino and Blasi 2009). According to the efficiency model, 
an inefficient response is characterized by low performance paralleled by increased 
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investment of neural resources, consisting in greater brain activity or recruitment of 
additional brain areas (Callicott et al. 2003; Van Snellenberg et al. 2015). The significance of 
the correlation appeared driven by the BRO condition. This result may be interpreted as 
reflecting a drug effect, but it is difficult to reach a conclusion at the current stage based only 
on the negative finding in the PLA condition. 
 
In this study, individuals with extreme allelic patterns, i.e., having either low or high 
predicted co-expression of the gene set including DRD2 in the DLPFC, exhibited similar 
response to D2R stimulation compared with intermediate allelic configurations. In particular 
on PLA, individuals with extreme genotype configurations had a decrease in differential 
accuracy and an increase in BOLD response during 3-Back with respect to 2-Back, reflecting 
a phenotype of inefficiency. It is important to note that these findings have been obtained in 
healthy subjects likely reflecting the physiological portion of the inverted-U curve. This 
finding also follows the inverted U-shaped relationship between WM processing and DA-
signalling (Cools and D'Esposito 2011). (Seamans and Yang 2004) reviewed evidence on D1 
receptors strongly supporting this model and also noted that PFC D2 receptors effectively 
exert opposite effects with respect to D1-mediated activity. Based on such a model, while 
individuals with allelic patterns predicting intermediate co-expression levels of the DRD2 
gene set display optimal WM processing, individuals with extreme alleles may be at a 
disadvantage because of insufficient or excessive D2-related activity. For example, 
individuals with high DRD2 gene set co-expression in the DLPFC may be less efficient in 
terms of WM processing reflecting a proneness to a D2-status characterized by low signal to 
noise ratio (Kahnt et al., 2015; Seamans and Yang, 2004). Given the strong relationship 
between executive function and WM capacity (McCabe et al. 2010; Johnson et al. 2013), this 
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phenotype of inefficiency may be associated with WM capacity limits. These findings 
highlight that the model put forward by (Seamans and Yang 2004) of a D2-dominated status 
is associated with the co-expression of a gene set, and not just with the DRD2 gene. 
Interestingly, this pattern was reversed following BRO administration. This finding suggests 
that healthy people with allelic patterns reflecting high or low co-expression of the DRD2 
gene set associated with inefficient WM processing were the same who benefitted most from 
the effect of D2R stimulation with BRO.   
It is difficult to put forward a mechanistic explanation of this "bidirectional" effect of BRO. 
One might expect that individuals with low PCI (lower predicted DRD2 co-expression) could 
benefit more from a D2R agonist than individuals with high PCI (higher predicted DRD2 co-
expression). Instead, our findings show that individuals with low WM capacity, whether 
associated with high or low PCI, showed greater improvement under BRO than those with 
intermediate PCI values. These findings are consistent with evidence from animal 
(Marighetto et al. 2008; Tarantino et al. 2011) and human (Kimberg et al. 1997) studies, and 
with previous reports showing that individuals carrying alleles associated with phenotypes of 
inefficiency are likely to show a higher magnitude of drug effect (Bertolino et al. 2004; Blasi 
et al. 2013; 2015). 
To explain why a D2R agonist in the current data appeared to act as a buffering agent (i.e., 
acting to the benefit of most extreme genotypes in both directions of the curve), it should be 
considered that the PCI has been developed as an index of mRNA co-expression in the 
DLPFC, thus it approximates post-synaptic DRD2 mRNA (primarily the long isoform; 
Pergola et al. 2017), together with the expression of its partner genes. However, BRO also 
acts on presynaptic receptors, which are not monitored by the PCI. Moreover, the PCI does 
not index either DA levels or D1, both involved in WM modulation. In our previous work, we 
23 
 
reported that the DRD2 co-expression gene set was functionally enriched for “negative 
regulation of dopamine secretion” (GO:0033602). On this account, it is possible that the 
transcriptomic context of DRD2 exerts an effect on DA levels, and further biological 
experiments are warranted to test this hypothesis at cell level. Finally, the co-expression 
module is not a proxy for only post-synaptic D2 receptors, but accounts for the co-expression 
of many other genes which may or may not be sensitive to DA neurotransmission – this 
remains to be tested. 
In our previous work (Gelao et al. 2014) we showed that a single functional SNP within the 
DRD2 gene predicted brain and behavioural effects of bromocriptine during WM processing. 
In the present study, we showed that that multiple alleles that co-vary with DRD2 expression 
are associated with brain and behavioural response to D2R stimulation. As in our previous 
study (Pergola et al. 2017), the PCI effect persisted when we covaried by rs1076560 (data 
available upon request). Notably, we did not observe a main effect of drug on differential 
accuracy, thus BRO administration in this study appeared to be either advantageous or 
detrimental depending on a complex, polygenic background of individuals. This finding is 
particularly relevant to pharmacogenomics because it supports the idea that allelic patterns, 
rather than specific alleles, may be associated with phenotypes of clinical interest, such as 
drug effect on brain processing.  
 
DRD2 PCI is associated with prolactin peripheral levels 
The findings on prolactin peripheral levels are consistent with the well-known effect of D2R 
agonists on prolactin peripheral levels (Berry and Gudelsky 1991). Since the PCI is based on 
DLPFC gene expression data, this finding may suggest that the genetic variants detected by 
(Pergola et al. 2017) affect DA signalling on multiple brain sites, and not only in the DLPFC. 
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However, further studies are needed to test this hypothesis more specifically. These findings 
are also in line with the evidence that genetic markers can be used to stratify prolactin 
response in patients (Sukasem et al. 2016) and support the idea that the SNPs included in the 
PCI predict DRD2 transcription. This is of particular interest for the treatment of psychosis 
because hyperprolactinemia and related sexual dysfunctions are common side effects of D2R 
blockade exerted by antipsychotics (Peveler et al. 2008). One limitation of this finding is that 
we did not control for menstrual phase. Although we attempted to control for this confound 
by including the factor gender in all analyses, this limitation may undermine the signal to 
noise ratio in females. 
Taken together, the present findings suggest that a gene set co-expressed with DRD2 and 
indexed by the PCI is associated with multiple D2R-dependent phenotypes, also including 
systemic response to pharmacological challenge.  
 
Limitations 
BRO targets multiple receptors, and not only the D2Rs (Sautel et al. 1995). Furthermore, 
BRO exerts its effect on both short and long isoforms of D2R (Gardner and Strange 1998; 
Gelao et al. 2014), while the PCI is primarily associated with D2 long-specific mRNA. Thus, 
it is not possible to elaborate a synaptic model of how BRO interacts with the PCI on the 
phenotypes we considered. While the bromocriptine study is well-powered compared to other 
similar studies (Kimberg et al. 2001; Bloemendaal et al. 2015), a sample size of 50 
individuals is small in the context of a genetic study (Casey et al. 2010). For this reason, we 
avoided excluding participants with extreme values, because they represent extreme 
genotypic configurations. Furthermore, the behavioural effects here reported have a moderate 
size which is comparable with similar findings with polygenic approaches (Cohen 1988; 
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Pergola et al. 2016), but greater samples are likely required to resolve the ambiguity of the 
behavioural results, which were not significantly replicated in the second sample. 
Importantly, we used differential accuracy as an index of WM capacity, reflecting more 
consistent accuracy in the face of load increase. Since the quadratic PCI effect was not found 
on accuracy scores irrespective of load, the present study does not provide direct evidence of 
an inverted-U relationship on WM accuracy indexed as percentage of correct responses. 
Sample size may also affect the fMRI results. In particular, we found that the repeated 
measures models we employed were more sensitive to artefacts compared to simpler models 
(e.g., the single session design of the replication dataset). Therefore, we employed correction 
tools for the main analysis (Mazaika et al., 2009) and a pre-processing pipeline designed to 
minimize signal loss. To discount the risk of type I error possibly associated with artefact 
correction, we sought replication of the results in our previously published dataset (Pergola et 





The present findings suggest that the role of DA signalling mediated by D2R in WM is 
associated with genetic variants in multiple genes co-regulated with DRD2. Together with the 
results of our previous study, the present evidence reveals both linear and non-linear 
relationships between genetically predicted DRD2 co-expression and brain and behavioural 
correlates of WM. Non-linear effects only emerged in the present study when load 
differences were taken into account. Inter-individual variation in WM brain/behavioural 
response takes the form of an inverted U-shaped relationship with predicted DRD2 co-
expression levels that is reversed when individuals are challenged with BRO. Importantly, 
this implies that individuals with opposite allelic patterns can show similar drug response, 
depending on the downstream physiological correlates of genetic variation. In conclusion, the 
present work provides novel information on the genetic architecture of WM capacity and 
related PFC activity and encourages both pharmacogenomics and imaging genetics to study 
allelic patterns associated with molecular phenomena such as gene co-expression to predict 
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Table 1. Sociodemographic characteristic of the three samples (mean + SD). IQ: intelligent quotient, WAIS-R:  




Table 2. Single Nucleotide Polymorfisms (SNPs) used to compute the PCI. MAF: minor allele frequency in the 
Braincloud sample. LD: Linkage disequilibrium. SNPs in Linkage Disequilibrium were identified in the 1000 
Genome Pilot 1 dataset with SNP Annotation and Proxy Search (SNAP, Broad Institute, 
http://archive.broadinstitute.org/mpg/snap/, and the following criteria: R2 threshold= 0.8; search window= 500 
kbp, Caucasian sample). 
 
Rank Marker Locus Gene Gene name Position SNPs in LD MAF 
1 rs2486064 1q32.1 CHIT1 Chitinase 1 
chr1:203199636 
- 0.22 






3 rs851436 2p24.1 OSR1 
Odd-Skipped 



















































50 27 27+4.1 113+12 47+16 0.77+0.35 
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Table 3. Statistics of the FWE-corrected clusters for the PCIquadratic×drug interaction at a cluster-defining 



































Region Brodmann Area 
MNI coordinates 





















Right BA47 42, 30, -6 17.97 3.70 
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Figure 1. Scatterplot of the drug by the quadratic term of the Polygenic Co-Expression Index 
(PCI) interaction on behavioral data. On the Y axis, ΔWM index refers to the unstandardized 
residuals of the model (see text). The X axis illustrates the PCI, which is directly proportional 
to predicted DRD2 gene set co-expression. On Placebo, individuals with extreme genotype 
configurations, i.e., with either low or high predicted DRD2 expression in the dorsolateral 
prefrontal cortex (DLPFC), exhibited a greater decrease in accuracy during 3-back with 
respect to 2-back compared to subjects with intermediate PCI. This pattern was reversed 
following Bromocriptine administration. 
 
 
Figure 2. (A) Sections of the brain showing the significant clusters in which the drug by 
quadratic term of the Polygenic Co-Expression Index (PCI) interaction was found. (B) 
Scatterplots of the BOLD measure (unstandardized residuals) extracted from the pooled 
prefrontal clusters against the PCI, showing the quadratic relationship and the inversion of 
the pattern after Bromocriptine administration. (C) Scatterplots of the BOLD measure 
(unstandardized residuals) extracted from the replication data against the PCI, showing the 
replication of the quadratic relationship independent on drug or placebo administration.   
 
 
 
 
 
